perifosine + docetaxel + prednisone

**perifosine + docetaxel + prednisone** is a three-drug combination therapy investigated primarily in oncology. - **Perifosine** is an oral alkylphospholipid and small molecule inhibitor that blocks signaling via the PI3K/AKT pathway, impeding tumor proliferation and survival[2][4][6]. - **Docetaxel** is a microtubule inhibitor (taxane class) that stabilizes microtubules, preventing cell division and inducing apoptosis in cancer cells[3][7]. - **Prednisone** is a synthetic glucocorticoid corticosteroid, used for its anti-inflammatory effects, and in this context to reduce adverse effects and possibly enhance efficacy of chemotherapy[1][3][7]. This triple regimen is investigated to reduce gastrointestinal toxicity relative to perifosine + docetaxel. It has been explored in the context of advanced solid tumors, including metastatic castration-resistant prostate cancer and potentially other difficult-to-treat cancers[5]. Prednisone addition decreases GI side effects in this combination[5], and perifosine offers potential synergy via PI3K/AKT pathway inhibition with chemotherapy. This regimen is under investigation; perifosine has not shown significant benefit as monotherapy but is being evaluated for possible synergy in combinations[2][5].